论文部分内容阅读
药物tenapanor是一种肠道钠/质子交换器亚型3(NHE3)的最小程度的系统性的抑制剂。在2014年美国费城举办的美国肾脏病学会周上,研究者表示,名为tenapanor的新药可帮助减少肾病患者机体的磷素吸收。此前研究显示,药物tenapanor可减少钠的吸收,在肾病周上演讲的第一项研究中研究人员表示,他们利用了两种动物模型确定了是否药物tenapanor可以减少机体磷的吸收。研究者发现,相比对照组来讲,tenapanor在啮齿类动物模型中可通过增加粪便中磷的排出,从而减少磷的吸收;而在第二种动物模型中研究者检测了心脏血管疾病的效应,结果显示,接受tenapanor的动物模型机体中的血管钙化标记物水平下降了,研究结
The drug tenapanor is a minimally systemic inhibitor of gut sodium / proton exchanger subtype 3 (NHE3). At the 2014 American Society of Nephrology week in Philadelphia, USA, researchers said a new drug called tenapanor helps reduce the body’s phosphorus uptake in kidney disease patients. Previous studies have shown that the drug tenapanor reduces sodium absorption, and in the first study that addressed the kidney neoplasia week, researchers said they used two animal models to determine whether the drug tenapanor reduces the body’s phosphorus uptake. The researchers found that tenapanor reduced phosphorus uptake in rodent models by increasing the excretion of phosphorus in the faeces compared to the control group; in the second animal model, researchers examined the effects of cardiovascular disease The results showed that the levels of vascular calcification markers in the animal model of the tenapanor decreased,